Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
PRME Prime Medicine Inc
- Stocks
- Healthcare
- NASDAQ: PRME
Price (delayed)
$1.615
Market cap
$212.04M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.61
Enterprise value
$227.25M
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime
Highlights
PRME's gross profit is up by 29% from the previous quarter
PRME's revenue is up by 29% QoQ
PRME's debt has surged by 197% since the previous quarter and by 177% year-on-year
Prime Medicine's equity has plunged by 56% YoY and by 30% from the previous quarter
Key stats
What are the main financial stats of PRME
Market
Valuations
Earnings
Shares outstanding
131.29M
Market cap
$212.04M
Enterprise value
$227.25M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.98
Price to sales (P/S)
54.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
59.09
Revenue
$3.85M
Gross profit
$3.85M
Operating income
-$206.52M
Net income
-$202.01M
EBIT
-$202.15M
EBITDA
-$184.21M
Free cash flow
-$111.41M
Per share
Balance sheet
Liquidity
EPS
-$1.61
EPS diluted
-$1.61
Free cash flow per share
-$0.85
Book value per share
$0.82
Revenue per share
$0.03
TBVPS
$2.51
Total assets
$328.16M
Total liabilities
$221.24M
Debt
$121.15M
Equity
$106.92M
Working capital
$129.48M
Debt to equity
1.13
Current ratio
4.78
Quick ratio
4.62
Net debt/EBITDA
-0.08
Margins
Efficiency
Dividend
EBITDA margin
-4,789.7%
Gross margin
100%
Net margin
-5,252.5%
Operating margin
-5,369.7%
Return on assets
-66.3%
Return on equity
-125.1%
Return on invested capital
-97.6%
Return on capital employed
-68.8%
Return on sales
-5,256%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PRME stock price
How has the Prime Medicine stock price performed over time
Intraday
7.67%
1 week
4.19%
1 month
1.57%
1 year
-74.57%
YTD
-44.69%
QTD
-18.84%
Financial performance
How have Prime Medicine's revenue and profit performed over time
Revenue
$3.85M
Gross profit
$3.85M
Operating income
-$206.52M
Net income
-$202.01M
Gross margin
100%
Net margin
-5,252.5%
PRME's net margin has surged by 85% year-on-year and by 20% since the previous quarter
The operating margin has surged by 85% year-on-year and by 21% since the previous quarter
PRME's gross profit is up by 29% from the previous quarter
PRME's revenue is up by 29% QoQ
Price vs fundamentals
How does PRME's price correlate with its fundamentals
Growth
What is Prime Medicine's growth rate over time
Valuation
What is Prime Medicine stock price valuation
P/E
N/A
P/B
1.98
P/S
54.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
59.09
The EPS has grown by 26% YoY and by 2.4% from the previous quarter
Prime Medicine's equity has plunged by 56% YoY and by 30% from the previous quarter
PRME's price to book (P/B) is 24% lower than its last 4 quarters average of 2.6
The P/S is 88% below the last 4 quarters average of 449.9
PRME's revenue is up by 29% QoQ
Efficiency
How efficient is Prime Medicine business performance
The ROS has soared by 85% YoY and by 20% from the previous quarter
The return on invested capital has grown by 26% year-on-year and by 7% since the previous quarter
The return on equity has declined by 25% since the previous quarter and by 24% year-on-year
Prime Medicine's return on assets has increased by 17% YoY
Dividends
What is PRME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PRME.
Financial health
How did Prime Medicine financials performed over time
PRME's total assets is 48% greater than its total liabilities
The total liabilities has surged by 53% since the previous quarter
The quick ratio has decreased by 50% YoY and by 14% from the previous quarter
PRME's debt is 13% greater than its equity
PRME's debt has surged by 197% since the previous quarter and by 177% year-on-year
Prime Medicine's equity has plunged by 56% YoY and by 30% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.